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Abstract
 
NK T cells are a unique subset of T cells that recognize lipid antigens presented by CD1d. After
activation, NK T cells promptly produce large amounts of cytokines, which may modulate the
upcoming immune responses. Previous studies have documented an association between de-
creased numbers of NK T cells and the progression of some autoimmune diseases, suggesting
that NK T cells may control the development of autoimmune diseases. To investigate the role
of NK T cells in autoimmune diabetes, we crossed CD1 knockout (CD1KO) mutation onto
the nonobese diabetic (NOD) genetic background. We found that male CD1KO NOD mice
exhibited significantly higher incidence and earlier onset of diabetes compared with the het-
erozygous controls. The diabetic frequencies in female mice showed a similar pattern; however,
the differences were less profound between female CD1KO and control mice. Early treatment
 
of NOD mice with 
 
 
 
-galactosylceramide, a potent NK T cell activator, reduced the severity of
autoimmune diabetes in a CD1-dependent manner. Our results not only suggest a protective
role of CD1-restricted NK T cells in autoimmune diabetes but also reveal a causative link be-
tween the deficiency of NK T cells and the induction of insulin-dependent diabetes mellitus.
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Introduction
 
Nonobese diabetic (NOD)
 
*
 
 mice, which develop autoim-
mune (type I) diabetes spontaneously, have long been used
as animal models to study the mechanisms involved in in-
sulin-dependent diabetes mellitus (IDDM) in humans (1).
In female mice, inflammation of the pancreatic islets (insu-
litis) usually begins at 
 
 
 
3–5 wk of age, eventually leading
to 
 
 
 
 cell destruction and overt diabetes by 4–6 mo of age.
Both CD4
 
 
 
 T cells, especially the Th1 subset, which pref-
erentially secretes IFN-
 
 
 
 and TNF-
 
 
 
, and CD8
 
 
 
 T cells
have been implicated in the pathogenesis of IDDM (2–5).
In parallel with these effector cells, the presence of regula-
tory T cells in prediabetic NOD mice that can block the
development of IDDM has been suggested by adoptive
transfer studies. These include CD4
 
 
 
CD62L
 
 
 
 thymocytes
(6), CD4
 
 
 
CD25
 
 
 
 splenocytes (7), and NK T cells (8–10).
Although the mechanisms of action of the regulatory T
cells are not fully understood, it is believed that an imbal-
ance between autoreactive effector T cells and regulatory T
cells may trigger the development of destructive insulitis
and IDDM. 
NK T cells are a unique subset of T cells that coexpress
receptors of the NK lineage and 
 
 
 
/
 
 
 
 TCR. Most NK T
cells express an invariant TCR 
 
 
 
 chain encoded by the
V
 
 
 
14J
 
 
 
281 gene segment, paired preferentially to V
 
 
 
8,
V
 
 
 
7, and V
 
 
 
2 chain (11). V
 
 
 
14
 
 
 
 NK T cells recognize
lipid antigens presented by the MHC class I–like molecule
CD1d (12). Similar subsets of T cells are also present in hu-
mans (13). CD1d-restricted NK T cells localize preferen-
tially to thymus and liver and are mainly of CD4
 
 
 
 or
CD4
 
 
 
CD8
 
  
 
phenotype (14). Upon TCR stimulation, NK
T cells promptly produce large amounts of cytokines, in-
cluding IL-4 and IFN-
 
 
 
 (11). In addition, NK T cells have
cytotoxic effects to certain targets, such as tumor cells and
immature thymocytes (15, 16). Although the physiological
ligand for CD1-restricted NK T cells is unknown, 
 
 
 
-galac-
tosylceramide (
 
 
 
-GalCer), a glycolipid isolated from marine
sponges that specifically binds CD1d, has been shown to be
a potent activator for V
 
 
 
14
 
 
 
 NK T cells (17). After injec-
tion of 
 
 
 
-GalCer into mice, the activation of NK T cells
results in rapid production of cytokines, which leads to acti-
vation of cell types involved in both innate immunity (NK
cells and dendritic cells) and adaptive immunity (T cells and
B cells) (18–21). Recent studies indicated that NK T cells
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may be involved in various immune responses, including
tumor rejection (22), early protection of infectious agents
(23, 24), and regulation of autoimmune diseases (25, 26).
The potential role of NK T cells in autoimmune diabetes
is suggested by the finding that the number and function of
NK T cells is diminished in the thymus and peripheral lym-
phoid organs of young NOD mice (8, 25, 27). In particu-
lar, anti-CD3–induced IL-4 secretion is barely detectable
in young NOD mice (27). Adoptive transfer of cell popula-
tions enriched for NK T cells prevents IDDM in NOD re-
cipients (8–10). Thus, a relative lack of IL-4 production by
NK T cells is associated with and might be causal to the
onset of IDDM. This notion is further supported by the
observation that the frequency of IL-4–producing NK T
cells is decreased in the peripheral blood of patients with
IDDM (28). 
In this study, we directly addressed the question of
whether functional deficiency in NK T cells has a causative
effect on the onset of IDDM by comparing the cumulative
incidence of diabetes and progression of insulitis in CD1-
deficient NOD mice with CD1-heterozygous controls.
We also examined the effect of 
 
 
 
-GalCer treatment on the
development of diabetes in NOD and CD1-deficient
NOD mice. We found that lack of CD1-restricted NK T
cells promotes the development of diabetes, whereas acti-
vation of V
 
 
 
14
 
 
 
 NK T cells by 
 
 
 
-GalCer suppresses dis-
ease in the NOD model. Our data suggests that NK T cells
could be used as therapeutic targets to modulate autoim-
mune diabetes.
 
Materials and Methods
 
Generation and Genotyping of CD1-deficient NOD Mice.
 
Spe-
cific pathogen–free NOD/Lt and B6 mice were purchased from
The Jackson Laboratory. In our NOD colony, the incidence of
spontaneous diabetes at 24 wk is 
 
 
 
70% in females and 20% in
males. CD1-deficient mice were generated by homologous re-
combination in our laboratory as described previously (29) and
were backcrossed up to nine generations onto NOD/Lt back-
ground and then intercrossed to generate CD1
 
 
 
/
 
 
 
 and CD1
knockout (CD1KO) NOD mice. The CD1 genotype was deter-
mined with PCR using the following three primers: CD1-for, 5
 
 
 
-
ATGTTTGATGGCTGCCTCTGCTCACTG-3
 
 
 
; CD1-rev,
5
 
 
 
-TGAGTACAGAGAAGCCAGTGGCCTGGT-3
 
 
 
; and neo-,
5
 
 
 
-CCAAGTGCCCAGCGGGGCTGCTAAAG-3
 
 
 
, which yields
a 150-bp fragment for the mutated allele and 330-bp fragment for
the wild-type allele. At the third backcross generation, three dia-
betes susceptibility loci, 
 
MHC I-A
 
g7
 
 (for 
 
Idd1
 
), 
 
D3Mit5
 
 (for 
 
Idd3
 
),
and 
 
D3Nds7
 
 (for 
 
Idd10
 
), were screened by PCR as described by
Lenschow et al. (30). The specific primers used are as follows:
for 
 
I-A
 
g7
 
, 5
 
 
 
-TGTCTTTTCTGTCACCCTAGAACA-3
 
 
 
 and
5
 
 
 
-CTCTTCAGGCTGGGATGCTCCAC-3
 
 
 
; for 
 
D3Mit5
 
, 5
 
 
 
-
AGCCCCTTCCAAGTGTCTCT-3
 
 
 
 and 5
 
 
 
-GGTTTCGGAA-
TGAGATGAGC-3
 
 
 
; and for 
 
D3Nds7
 
, 5
 
 
 
-TGCTCCTCACCA-
GTCATGC-3
 
 
 
 and 5
 
 
 
-TAGTGTTTGCCATGGCTCTC-3
 
 
 
. The
PCR products were resolved on a 4% agarose gel. The CD1
 
 
 
/
 
 
 
mice homozygous for the 
 
NOD
 
 allele in 
 
I-A
 
g7
 
 and 
 
D3Mit5
 
 loci
were selected for further backcross.
 
Histopathology. 
 
Pancreatic tissues were harvested at various
time points, fixed with 10% buffered formalin, and embedded in
paraffin. Four serial 5-
 
 
 
m sections were cut at intervals of 100
 
 
 
m and stained with hematoxylin and eosin. A minimum of 30
islets from each animal was examined. The severity of insulitis
was determined and graded using the following criteria according
to the magnitude of mononuclear cell infiltration: grade 0, no
mononuclear cell infiltration; grade 1, periinsulitis, mononuclear
cells surrounding islets and ducts but no intraislet infiltration;
grade 2, mononuclear cell infiltration in and around the islet, but
intraislet infiltration in 
 
 
 
20% of the islet area; grade 3, intraislet
mononuclear cell infiltration in 20–50% of the islet area; grade 4,
extensive intraislet infiltration occupying 
 
 
 
50% of the islet area. 
 
Assessment of Diabetes. 
 
Starting at 10 wk of age, the urinary
glucose analysis was performed every 2 wk with Diastix
 
®
 
 reagent
strips (Bayer Corporation). Hyperglycemia was confirmed by
blood glucose determination with ONE-TOUCH
 
®
 
 test strips
(LifeScan, Inc.). Animals were considered diabetic after their
urine glucose levels were 
 
 
 
500 mg/dl for two consecutive days
and their blood glucose levels were 
 
 
 
250 mg/dl.
Figure 1. Increased onset and incidence of diabetes in CD1KO NOD
mice. CD1KO mice were backcrossed six to nine generations onto
NOD/Lt background and then intercrossed to generate CD1    and
CD1KO NOD mice. Beginning at 10 wk of age, the urine glucose levels
of NOD mice were monitored every 2 wk. Male (top) and female (bot-
tom) mice were considered to have developed diabetes if two consecutive
glucosuria levels were  500 mg/dl and blood glucose levels were  250
mg/dl.  , homozygous CD1-deficient NOD mice;  , CD1 heterozy-
gous NOD littermate mice. 
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In Vivo 
 
 
 
-GalCer Treatment.
 
A synthetic form of 
 
 
 
-GalCer,
KRN7000, was used to treat NOD and CD1KO NOD mice. At
3 wk of age, the mice in the experiment group were injected
twice per week intraperitoneally with 2 
 
 
 
g per mouse of
KRN7000 in 200 
 
 
 
l of 0.025% polysorbate-20 in PBS, and the
control mice were injected with 0.025% polysorbate-20 in PBS.
 
In Vitro Activation of Lymphocytes and Analysis of Cytokine Pro-
duction.
 
CD8
 
 
 
 T cells and B cells were depleted from the sple-
nocytes of CD1KO NOD or CD1
 
   
 
 NOD mice by incubating
cells with CD8
 
 
 
–FITC and B220–FITC (PharMingen) and then
incubated with avidin–magnetic beads and applied to magnetic
separation (PerSeptive Biosystems). The CD4
 
 
 
-enriched cells
(5 
 
  
 
10
 
5
 
 cells per well) were stimulated with either 100 ng/ml of
 
 
 
-GalCer or with an anti-CD3 (2C11) coated 96-well plate in a
final volume of 200 
 
 
 
l of RPMI 1640 medium (supplemented
with 10% FCS, 2 mM 
 
l
 
-glutamine, 20 
 
 
 
M 2-ME, and 100 U/ml
penicillin/streptomycin). After 48 h, the culture supernatants
were harvested, and the levels of IL-4 and IFN-
 
 
 
 were quanti-
tated by ELISA (PharMingen).
 
Statistical Analysis.
 
The time course of spontaneous diabetes
onset was analyzed using the Kaplan Meier curve. The curves
were tested for significance by log-rank test. Mean values for cy-
tokine levels and degree of insulitis were compared using the un-
paired Student’s 
 
t
 
 test. Statistical significance was considered to be
 
P 
 
  
 
0.05. All statistical analyses were performed with the Prism
 
®
 
program (GraphPad Software, Inc.).
 
Results
 
Increased Incidence of Diabetes in CD1-deficient NOD
Mice.
 
The CD1KO mutation replaced a 12-kb DNA frag-
ment encompassing exon 4–6 from both 
 
CD1d1
 
 and
 
CD1d2
 
 with a neomycin-resistant cassette, which resulted in
a complete loss of CD1 expression and impaired NK T cell
development in homozygous mutant animals (29). We
crossed the CD1KO mutation onto the NOD/Lt back-
ground to investigate the role of CD1-restricted NK T cells
in the regulation of autoimmune diabetes. The development
of diabetes in CD1KO NOD and control mice (from six to
nine generations backcrossed) was monitored at biweekly
intervals beginning after 10 wk of age. As seen in Fig. 1,
 
 
 
50% of the male CD1KO NOD mice were hyperglyce-
mic by 40 wk of age, as compared with only 20% of the
male CD1
 
   
 
 NOD mice. Nearly 15% of the male CD1KO
NOD mice developed diabetes by 20 wk of age, while all
the CD1    controls were diabetes free within the same pe-
riod. This data suggests that CD1 deficiency not only results
in an increased incidence of diabetes but also accelerates the
onset of diabetes in male NOD mice (P   0.05; n   51 and
43 for CD1KO and CD1   , respectively). Although the fe-
male CD1KO NOD mice also displayed a slightly increased
incidence of diabetes over a period of 32 wk (P   0.05; n  
43 and 41 for CD1KO and CD1   , respectively), we ob-
served no significant differences in the onset of diabetes be-
tween the female CD1KO NOD and CD1    controls.
A hallmark of the NOD mouse model for IDDM is the
progressive infiltration of mononuclear cells into the pan-
creatic islets. In our wild-type NOD colony, insulitis be-
comes noticeable at 5–6 wk of age in females and 10–12
wk of age in males. To quantitate the development of insu-
litis, 30–40 islets from individual CD1KO NOD and het-
erozygous control mice (nine generations backcrossed)
were assessed for the severity of insulitis (Fig. 2). In the
male CD1    NOD mice, almost 70% of islets are free of
infiltrating cells at 12 wk of age, at which time  40% of is-
lets from CD1KO NOD mice are free of insulitis (n   5,
P   0.05). At 16 wk of age, 35–45% of islets from CD1   
controls still have no detectable insulitis, while only 10–
15% of islets from CD1KO NOD male mice are free of in-
filtrating cells (n   4, P   0.05). In addition, the percent-
ages of islets with heavy infiltrates (grades 3 and 4) were
also significantly greater in CD1KO groups. In contrast, we
found no significant difference in the degree of insulitis be-
tween female CD1KO NOD mice and their heterozygous
littermate controls at 6, 9, and 12 wk of age (Fig. 2).
Reduced IL-4 and IFN-  Secretion in CD1-deficient NOD
Mice. Cytokine imbalance has been attributed to be one
of the mechanisms to trigger the development of autoim-
mune diabetes (31). To investigate whether lack of CD1-
restricted NK T cells affects the balance between Th1 and
Figure 2. Histopathologic examination of pancreatic in-
sulitis in CD1KO NOD and CD1    NOD littermates.
Pancreatic tissues were taken at serial time points. After he-
matoxylin and eosin staining, a minimum of 30 islets from
each mouse was examined. The severity of insulitis was
determined and graded semiquantitatively using the criteria
as described in Materials and Methods. Data shown repre-
sent mean of four to five animals in each age group.316 CD1-restricted NK T cells in Autoimmune Diabetes
Th2 cells in NOD mice, we analyzed the cytokine profile
of CD4  T cells from CD1KO and control littermates
upon anti-CD3 stimulation in vitro. As shown in Fig. 3 A,
splenic CD4  T cells from both male and female CD1KO
NOD mice produced significantly lower quantities of IL-4
compared with heterozygous control mice in all of the age
groups (n   5, P   0.05). We found considerable variabil-
ity in the levels of IFN-  produced in individual mice with
no statistical significance between CD1KO and heterozy-
gous littermate controls (Fig. 3 A). Thus, lack of IL-4 se-
creted by NK T cells did not promote the Th1 response in
CD1KO NOD mice. Nevertheless, the ratios of IFN- /
IL-4 are consistently greater in CD1KO NOD mice than
those in the control mice (Fig. 3 B), which might be an
important factor in controlling the IDDM.
 -GalCer Treatment Delays the Onset and Reduces the Inci-
dence of Diabetes in NOD Mice.  -GalCer has been shown
to be a potent immunostimulator for CD1-restricted NK T
cells both in vivo and in vitro (17). As NOD mice have di-
minished NK T cell activity compared with other strains of
mice, we examined whether  -GalCer can activate NK T
cells from NOD mice. Fig. 4 A shows that splenic T cells
from NOD mice secrete both IL-4 and IFN-  upon stimu-
lation with  -GalCer, although the response is significantly
weaker than that in B6 mice. To determine the effect of
enhanced NK T cell activity on the development of spon-
taneous autoimmune diabetes, NOD mice were treated,
starting at 3 wk of age, with  -GalCer or vehicle control.
Treating NOD mice with  -GalCer significantly reduced
the cumulative incidence of diabetes at the age of 32 wk
(from 80 to 40%, n   15, P   0.05; Fig. 4 B). There was
also a delayed onset of diabetes in  -GalCer–treated NOD
mice. None of the  -GalCer–treated mice developed dia-
betes before 16 wk of age, whereas nearly 30% of vehicle-
treated NOD mice had already developed diabetes. In con-
trast, treating CD1KO NOD mice with  -GalCer did not
have any effect on the development of diabetes. Therefore,
the effect of  -GalCer on the development of diabetes is
strictly CD1 dependent, presumably mediated through
CD1-restricted NK T cells.
To examine the effect of  -GalCer treatment on pre-
diabetic islet infiltration, we analyzed hematoxylin and
eosin–stained sections of pancreata from  -GalCer– and
vehicle-treated mice at weeks 3, 6, and 9 after the start of
treatment. As shown in Fig. 4 C, significantly greater per-
centages of islets were free of insulitis from  -GalCer–
treated mice than those from the control mice at all three
time points (n   5, P   0.05). Furthermore, the degree of
insulitis in  -GalCer–treated mice is less severe than that in
the vehicle-treated mice. Thus, activation of NK T cells by
 -GalCer suppressed the inflammatory infiltration of the
islets in NOD mice, which could subsequently delay the
onset and reduce the incidence of diabetes.
Discussion
As in human IDDM, diabetes development in NOD
mice is controlled by a number of disease susceptibility or
Figure 3. IL-4 and IFN-  production by splenic
T cells from CD1    and CD1KO NOD mice. (A)
The CD4 -enriched cells (5   105 cells per well)
from the indicated mice were cultured with immo-
bilized anti-CD3 (10  g/ml). Supernatants were
harvested 48 h later and assayed for IL-4 (top) and
IFN-  (bottom) by ELISA. (B) The ratio of IFN- /
IL-4 produced by T cells from CD1KO NOD and
littermate controls. Data shown represent mean  
SE of four to five mice in each group.317 Wang et al.
resistance genes (Idds). The CD1 gene is close to the Idd3
and Idd10 loci in murine chromosome 3 (32). Based on the
PCR typing (data not shown), all of the mice (CD1 KO
and CD1   ) used in this study were homozygous for the
NOD allele in Idd3 locus. The CD1 gene is tightly linked
with Idd10. The CD1    mice used in this study are het-
erozygous for the Idd10 locus, while CD1KO mice retain
the 129 allele. As CD1KO NOD mice contain one less
Idd-susceptible allele than controls, it is unlikely that the in-
creased susceptibility to diabetes is due to a linked gene car-
ried along during the backcross. Our observation of the ac-
celeration of autoimmune disease in CD1KO NOD mice
suggested that CD1-restricted NK T cells play a role in re-
sistance to diabetes in NOD mice even though NK T cell
function is genetically diminished relative to that in other
strains of mice (25). Activation of NK T cells with  -Gal-
Figure 4.  -GalCer protects NOD mice from developing IDDM. (A) In vitro ac-
tivation of spleen cells from NOD and B6 mice with  -GalCer. Spleen cells (5   105
cells per well) from the indicated mice were cultured with 100 ng/ml of  -GalCer.
2 d later, cytokine production in the culture supernatant was measured by ELISA.
Spleen cells cultured with vehicle (0.1% DMSO) did not secrete detectable amounts
of IFN-  and IL-4 ( 1 U/ml). (B) The effect of  -GalCer on the incidence of dia-
betes. Female NOD (top) and CD1KO NOD (bottom) mice were injected intra-
peritoneally twice per week with  -GalCer ( ) or 0.025% polysorbate-20 vehicle ( )
as described in Materials and Methods. Starting at 10 wk of age, diabetes was moni-
tored by measurements of urine and blood glucose levels. (C) The effect of  -GalCer
on the insulitis of NOD mice. Female NOD mice were treated with  -GalCer or
0.025% polysorbate vehicle starting at 3 wk of age, as described in Materials and
Methods. Pancreata were microscopically evaluated for the degree of insulitis as de-
scribed above. Data shown represent the mean of five animals in each group.318 CD1-restricted NK T cells in Autoimmune Diabetes
Cer inhibited IDDM development in NOD but not
CD1KO NOD mice, which further supports the protective
role of CD1-restricted NK T cells in autoimmune diabetes.
In the NOD model, there exists a remarkable gender
disparity in the cumulative incidence of diabetes, indicating
that female NOD mice might have a greater deficit in vari-
ous immunoregulatory mechanisms. Therefore, lack of
functional activity from NK T cells, one out of many im-
munoregulatory mechanisms, appears to have less profound
effect on the progression of diabetes in female NOD mice
than in male NOD mice. However, we cannot eliminate
the possibility that NK T cells may play a more dominant
role in regulating the IDDM in male NOD mice.
There are several distinct mechanisms that may explain
why lack of NK T cells in CD1KO NOD mice would
render them more susceptible to autoimmune disease. First,
lower levels of IL-4 detected in CD1KO NOD mice
might not be sufficient to stimulate mice to downregulate
Th1 diabetogenic cells. However, as IL-4KO NOD mice
do not develop accelerated disease (33), lack of IL-4 se-
creted by NK T cells could not be solely responsible for the
increased susceptibility to diabetes in CD1KO NOD mice.
A recent study showed that IFN-  secreted by NK T cells
in the periphery might be critical for protection against dia-
betes (10). Although the majority of CD1KO NOD mice
secreted lower levels of IFN-  compared with controls,
some CD1KO NOD mice produced more IFN-  than
their littermate controls, presumably from other CD4  T
cells. Thus, it is unlikely that lack of IFN-  secreted by NK
T cells would contribute significantly to the exacerbation
of IDDM in CD1KO mice. Second, NK T cells have been
shown to have a cytotoxic effect on immature thymocytes
(15), indicating that NK T cells may regulate T cell selec-
tion in the thymus. Therefore, lack of NK T cells might af-
fect the repertoire of autoreactive T cells. Third, NK T
cells or the expression of CD1 might be involved in main-
taining the survival and function of some regulatory T cells.
We performed FACS® analysis and found that CD1KO
NOD and heterozygous controls have comparable num-
bers of CD4 CD25  T cells (data not shown), a subset of
T cells that has been shown to be critical in controlling
spontaneous autoimmune diabetes (7). However, it re-
mains possible that other regulatory T cells might be af-
fected by CD1 deficiency.
Treatment with  -GalCer has been shown to modulate
several immune responses in vivo, such as enhancing the
antitumor (34) and antiviral activity (35), mediating protec-
tion against murine malaria (36), and regulating intestinal
inflammation (37). Here we showed that  -GalCer exerts a
protective effect on autoimmune diabetes in NOD mice.
The precise mechanism of how  -GalCer activates NK T
cells to protect IDDM is not clear. Previous studies showed
that in vivo administration of  -GalCer polarizes adaptive
immune response for production of Th2 cytokines (20,
21). However, we did not detect a polarized Th2 response
in  -GalCer–treated NOD mice (data not shown). It is
possible that activation of NK T cells by  -GalCer leads to
bystander activation of cell types (i.e., regulatory T cells,
NK cells, and dendritic cells) that are critical in regulating
the autoreactive T cells in NOD mice. Similar to mouse
NK T cells,  -GalCer can also activate human NK T cells
in a CD1d-dependent manner (38, 39). Thus, our results
suggest that activation of NK T cells by  -GalCer may rep-
resent a novel approach for therapeutic intervention of
IDDM in humans.
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